Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,164,732
  • Shares Outstanding, K 74,484
  • Annual Sales, $ 475,600 K
  • Annual Income, $ -418,260 K
  • 60-Month Beta 1.62
  • Price/Sales 36.34
  • Price/Cash Flow N/A
  • Price/Book 24.99
Trade NVAX with:

Options Overview Details

View History
  • Implied Volatility 69.57%
  • Historical Volatility 64.40%
  • IV Percentile 2%
  • IV Rank 6.81%
  • IV High 165.67% on 01/28/21
  • IV Low 62.55% on 06/24/21
  • Put/Call Vol Ratio 0.52
  • Today's Volume 25,178
  • Volume Avg (30-Day) 26,194
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 131,998
  • Open Int (30-Day) 132,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -4.04
  • Number of Estimates 4
  • High Estimate -3.12
  • Low Estimate -5.04
  • Prior Year -3.21
  • Growth Rate Est. (year over year) -25.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
222.10 +11.73%
on 08/27/21
277.80 -10.67%
on 09/08/21
+15.15 (+6.50%)
since 08/24/21
3-Month
172.01 +44.27%
on 07/27/21
277.80 -10.67%
on 09/08/21
+55.68 (+28.93%)
since 06/24/21
52-Week
76.59 +224.01%
on 11/10/20
331.68 -25.18%
on 02/09/21
+145.72 (+142.25%)
since 09/24/20

Most Recent Stories

More News
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility

AZN : 60.35 (+1.46%)
PFE : 43.94 (-0.57%)
MRNA : 430.14 (-5.38%)
NVAX : 248.16 (-3.55%)
Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, hosted HM King Carl XVI Gustaf...

NVAX : 248.16 (-3.55%)
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced publication...

NVAX : 248.16 (-3.55%)
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024 - Financial News Media

Palm Beach, FL - September 23, 2021 – FinancialNewsMedia.com News Commentary – The growth in the COVID-19 vaccine market is projected to continue to surge through 2024. This growth is attributable...

BIOV.CN : 0.495 (+1.02%)
BVAXF : 0.3954 (+4.27%)
DVAX : 19.83 (+1.17%)
INO : 7.76 (-3.36%)
NVAX : 248.16 (-3.55%)
VXRT : 8.17 (-3.31%)
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine

"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great...

NVAX : 248.16 (-3.55%)
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate...

NVAX : 248.16 (-3.55%)
As the Virus Continues, the Global COVID-19 Vaccine Market Expected to Reach $25 Billion By 2024

PALM BEACH,  Fla., /PRNewswire/ --  - The growth in the COVID-19 vaccine market is projected to continue to surge through 2024. This growth is attributable to drastic surge in coronavirus cases across...

BIOV.CN : 0.495 (+1.02%)
BVAXF : 0.3954 (+4.27%)
DVAX : 19.83 (+1.17%)
INO : 7.76 (-3.36%)
NVAX : 248.16 (-3.55%)
VXRT : 8.17 (-3.31%)
Novavax (NVAX) Gains As Market Dips: What You Should Know

Novavax (NVAX) closed at $230.29 in the latest trading session, marking a +1.49% move from the prior day.

NVAX : 248.16 (-3.55%)
Novavax to Participate in Fireside Chat at Devex @ UNGA 76

COMTEX_393685487/2669/2021-09-20T16:05:29

NVAX : 248.16 (-3.55%)
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation...

NVAX : 248.16 (-3.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as...

See More

Key Turning Points

3rd Resistance Point 265.94
2nd Resistance Point 261.62
1st Resistance Point 254.89
Last Price 248.16
1st Support Level 243.84
2nd Support Level 239.52
3rd Support Level 232.79

See More

52-Week High 331.68
Last Price 248.16
Fibonacci 61.8% 234.24
Fibonacci 50% 204.14
Fibonacci 38.2% 174.04
52-Week Low 76.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar